Detection method for monitoring β tubulin isotype specific modification
AssigneeTularik Inc.
InventorsHolger Beckmann, Edit Santha
Life of this patent
Estimating the term…
Abstract
This invention relates to monoclonal antibodies that recognize modified β-tubulin isotypes, methods of using such antibodies to detect modified β-tubulin isotypes, methods of using such antibodies to monitor β-tubulin modifying agents administered to a patient, methods of using such antibodies to isolate modified β-tubulin, and methods of detecting the anti-modified β-tubulin antibodies.
Claims17
A method of detecting in a sample a β-tubulin isotype modifed at a cysteine residue at amino acid position 239 by treatment with a sulfhydryl or disulfide β-tubulin modifying agent, the method comprising the steps of:
- (a) providing a sample treated with the β-tubulin modifying agent;
- (b) contacting the sample with an antibody that specifically binds to the β-tubulin isotype modified at the cysteine residue at amino acid position 239;
- and
- (c) determining whether the sample contains the β-tubulin isotype modified at the cysteine residue at amino acid position 239 by detecting the antibody.
A method of detecting in a sample a tubulin isotype modified at a cysteine residue, at amino acid position 239 the isotype modified by treatment with a sulfhydryl or a disulfide tubulin modifying agent, comprising the steps of:
- (a) providing a sample treated with the tubulin modifying agent;
- (b) contacting the sample with an antibody that specifically binds to the tubulin isotype modified at a cysteine residue at amono acid position 239;
- and
- (c) determining whether the sample contains the tubulin isotype modified at a cysteine residue at amino acid position 239 by detecting the antibody.
A method of monitoring the amount of a tubulin modified at a cysteine residue at amino acid position 239 in a patient treated with a sulfhydryl or a disulfide tubulin modifying agent, the method comprising the steps of:
- (a) providing a sample from the patient treated with the tubulin modifying agent;
- (b) contacting the sample with an antibody that specifically binds to the tubulin modified at a cysteine residue at amino acid position 239;
- and
- (c) determining the amount of the tubulin modified at a cysteine residue at amino acid position 239 in the patient sample by detecting the antibody and comparing the amount of antibody detected in the patient sample to a standard curve, thereby monitoring the amount of the tubulin modified at a cysteine residue at amino acid position 239 in the patient.
Dependencies are inferred from the claim text.